Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Cholesterol screening in asymptomatic adults, revisited

Article Abstract:

Cholesterol screening, and subsequent therapy to reduce cholesterol levels, may be most effective if limited to people with a high short-term risk of dying from coronary heart disease. Researchers analyzed several studies on the risks associated with high cholesterol levels and the effectiveness of cholesterol reduction. Lowering cholesterol levels reduces the risk of illness and death in people with coronary heart disease. However, such cholesterol reduction has been proven to reduce the death rate only among people with high-risk, such as heart attack survivors and middle aged men with other risks for heart disease. Much research has not been done on reducing cholesterol in young people and middle aged women, thus reduction therapy may not have significant benefits in these population. More research is needed to evaluate the risks and benefits of the various drugs for reducing cholesterol. Ultimately, screening is not effective if it does not lead to an effective therapy.

Author: Hulley, Stephen B., Browner, Warren S., Garber, Alan M.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
Evaluation, Measurement, Medical screening, Health screening, Cholesterol

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Hormone therapy to prevent disease and prolong life in postmenopausal women

Article Abstract:

Some postmenopausal women or women who have had a hysterectomy may choose to undergo hormone therapy. Hormone therapy consists of treatment with estrogen alone or estrogen combined with progestin to prevent certain diseases or to treat the symptoms of menopause. This type of therapy has both inherent benefits and risks. A survey of the medical literature found that hormone therapy reduces the risk of coronary heart disease and of a hip fracture as the result of osteoporosis. Treatment with estrogen may increase the risk of endometrial cancer in women with a uterus and breast cancer. The risk of endometrial cancer may be lower in women with a uterus who are treated with a combination of estrogen and progestin than in those treated with estrogen alone. Hormone therapy may be most suitable for women with an increased risk of coronary heart disease or for those who have had a hysterectomy.

Author: Cummings, Steven R., Black, Dennis, Grady, Deborah, Petitti, Diana B., Rubin, Susan M., Ernster, Virginia L., Fox, Cary S., Ettinger, Bruce
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1992
Care and treatment, Usage, Drug therapy, Hormone therapy, Menopause, Postmenopausal women

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: High blood cholesterol in elderly men and the excess risk for coronary heart disease. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women
  • Abstracts: Coffee, caffeine and cardiovascular disease in men. Vitamin E consumption and the risk of coronary heart disease in men
  • Abstracts: Cholesterol redux. Cholesterol and coronary heart disease: future directions. A single cholesterol measurement underestimates the risk of coronary heart disease: an empirical example from the lipid research clinics mortality follow-up study
  • Abstracts: Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease
  • Abstracts: Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers. Cryptosporidiosis and acute leukaemia
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.